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ABSTRACT Cells exposed to short and intense electric pulses become permeable to a number of various ionic molecules.
This phenomenon was termed electroporation or electropermeabilization and is widely used for in vitro drug delivery into the
cells and gene transfection. Tissues can also be permeabilized. These new approaches based on electroporation are used
for cancer treatment, i.e., electrochemotherapy, and in vivo gene transfection. In vivo electroporation is thus gaining even
wider interest. However, electrode geometry and distribution were not yet adequately addressed. Most of the electrodes used
so far were determined empirically. In our study we 1) designed two electrode sets that produce notably different distribution
of electric field in tumor, 2) qualitatively evaluated current density distribution for both electrode sets by means of magnetic
resonance current density imaging, 3) used three-dimensional finite element model to calculate values of electric field for both
electrode sets, and 4) demonstrated the difference in electrochemotherapy effectiveness in mouse tumor model between the
two electrode sets. The results of our study clearly demonstrate that numerical model is reliable and can be very useful in the
additional search for electrodes that would make electrochemotherapy and in vivo electroporation in general more efficient.
Our study also shows that better coverage of tumors with sufficiently high electric field is necessary for improved effective-
ness of electrochemotherapy.
INTRODUCTION
The application of short and intense electric pulses to cells
induces transient and reversible changes in the plasma
membrane so that it becomes permeable to a number of
various ionic molecules (Tsong, 1991). Electric conductiv-
ity of the plasma membrane in normal physiological con-
ditions is much lower than the conductivity of cytoplasm
and extracellular medium (Kotnik et al., 1997). When a cell
having a resting transmembrane potential is exposed to an
external electric field, the anode-facing side becomes hy-
perpolarized and the cathode-facing side becomes depolar-
ized depending on the size and the shape of the cell (Hibino
et al., 1991; Sers˘a et al., 1996b). If the externally induced
transmembrane potential is high enough, i.e., above a
threshold value, then permeabilization of plasma membrane
occurs (Kinosita et al., 1988), which results in local pertur-
bations in its structure and an increase of its permeability
(Zimmermann, 1986). At the molecular level, the phenom-
enon is still a subject of the research (Weaver and Chiz-
madzhev, 1996; Kakorin et al., 1996). Under appropriate
conditions, these membrane changes are reversible and cell
viability is maintained (Neumann et al., 1982; Rols and
Teissie, 1990). The phenomenon is called electroporation or
electropermeabilization.
Some chemotherapeutic drugs used in cancer therapy
have poor access into the tumor cells. Therefore, electroper-
meabilization offers an approach for increased drug delivery
into the cells and thus better antitumor effectiveness. It was
shown that in vitro cytotoxicity of some chemotherapeutic
drugs can be potentiated several-fold by exposing cells to
short intense electric pulses (Orlowski et al., 1988). Tissues
can also be electropermeabilized and thus the antitumor
effectiveness of chemotherapeutic drugs potentiated by in-
creasing drug delivery into the cells (Belehradek et al.,
1994). This novel approach, termed electrochemotherapy,
was introduced by M. Okino and L. M. Mir (Okino and
Mohri, 1987; Mir et al., 1991). For example, antitumor
effectiveness of bleomycin can be greatly potentiated by
electric pulses, inducing partial and complete responses of
the tumors. Furthermore, the treatment requires such a low
amount of bleomycin that it is ineffective without electric
pulses and does not induce side effects. Increased antitumor
effectiveness has also been shown for the chemotherapeutic
drug cis-diamminedichloroplatinum (II) (Sers˘a et al, 1995).
Numerous research groups tested electrochemotherapy
with bleomycin in different animal tumor models and ob-
served increased antitumor effectiveness (Mir et al., 1995a).
Cures were obtained in different murine tumor models,
either transplanted or spontaneous (Mir et al., 1991; Bele-
hradek et al., 1991; Sers˘a et al., 1994a; Heller et al., 1995).
Experiments with intratumoral injection of the drug
(C˘emaz˘ar et al., 1995; Heller et al., 1997) were carried out
in order to increase its efficiency. In addition, electroche-
motherapy was successfully combined with immunotherapy
using interleukin-2 (Mir et al., 1992; Mir et al., 1995b) and
tumor necrosis factor- (Sers˘a et al., 1997). The first clin-
ical phase I-II trial of electrochemotherapy has been per-
formed in Villejuif (France) on cutaneous permeation nod-
ules of head and neck carcinomas. Complete regression of
Received for publication 3 November 1997 and in final form 10 February
1998.
Address reprint requests to Dr. Damijan Miklavc˘ic˘, Faculty of Electrical
Engineering, University of Ljubljana, Trz˘as˘ka 25, 1000 Ljubljana,
Slovenia.
© 1998 by the Biophysical Society
0006-3495/98/05/2152/07 $2.00
2152 Biophysical Journal Volume 74 May 1998 2152–2158
50% of the tumors treated was observed (Belehradek et al.,
1993). Other clinical trials are in progress in Toulouse
(France), Tampa (FL) (Heller et al., 1996b), and Ljubljana
(Slovenia) (Rudolf et al., 1995) for the treatment of head
and neck carcinoma permeation nodules, melanomas, basal
cell carcinomas, and Kaposi skin cancers.
Besides this vast data on electrochemotherapy, electro-
poration is widely used for gene transfection in vitro and has
been shown lately to hold promises for in vivo gene trans-
fection, as well (Heller et al., 1996a; Nishi et al., 1996). As
it is increasingly accepted that in vivo gene transfer will be
the future direction for cancer therapy as well as for other
human diseases (Yang and Sun, 1995), the use of in vivo
electroporation is gaining even wider interest.
In our previous study we demonstrated that the electrode
configuration used was not the most appropriate for effi-
cient electrochemotherapy (Sers˘a et al., 1996b). Namely,
many tumors regrew in the areas where the intensity of the
electric field was presumably below threshold. A search for
better ways of electric field application was thus initiated
(Mir et al., 1997; Gilbert et al., 1997). The data on use of
different electrodes further substantiated the need to ap-
proach this problem more systematically. In fact, electrode
geometry and configuration used and tested so far were
determined empirically. Numerical modeling could be an
efficient tool for improvement of electric field distribution
and its control within the body.
As the underlying mechanism for electrochemotherapy is
understood to be electroporation requiring a certain pore
density, the onset of permeation is a threshold phenomenon.
A hypothesis can therefore be stated that electrochemo-
therapy is effective if all of the tumor is subjected to a high
enough (i.e., over threshold) electric field. In order to verify
this hypothesis in vivo and to determine the importance of
electric field distribution for effectiveness of electrochemo-
therapy we have: 1) designed two electrode sets that pro-
duce notably different distribution of electric field in tumor;
2) qualitatively evaluated current density distribution in
tumor for both electrode sets by means of magnetic reso-
nance (MR) current density imaging (CDI); 3) used a three-
dimensional finite element model of a mouse with subcu-
taneous tumor to calculate values of electric field in the
tumor for both electrode sets; and 4) demonstrated the
difference in electrochemotherapy effectiveness in mouse
tumor model between the two electrode sets.
MATERIALS AND METHODS
Animal tumor model
In experiments, an inbred strain of A/J mice of both sexes was used,
purchased from Rudjer Bos˘kovic´ Institute (Croatia). They were maintained
at a constant room temperature (24°C) with natural day and night light
cycle in a conventional animal colony. Before the experiments, the mice
were subjected to an adaptation period of at least 10 days. Mice in good
condition, without fungal or other infections, and 10–12 weeks of age were
included in experiments. Fibrosarcoma SA-1 tumor (The Jackson Labora-
tory, Bar Harbor, ME) syngeneic to A/J mice was used as a tumor model.
Tumor cells were obtained from the ascitic form of the tumors in mice
serially transplanted every 7 days. Solid subcutaneous tumors located
dorsolaterally were induced by an injection of 5 105 SA-1 cells in 0.1 ml
of 0.9% NaCl solution. The viability of the cells was over 95% as
determined by a trypan blue dye exclusion test.
Electrochemotherapy
Six to eight days after transplantation when the tumors reached 50 mm3
in volume, mice were randomly divided into experimental groups and
subjected to a specific experimental protocol.
Animal preparation for magnetic resonance
imaging (MRI) and CDI measurements
Eight A/J male mice bearing subcutaneous SA-1 fibrosarcoma on the left
flanks (dorsolaterally) were anesthetized prior to imaging with Rompun
(Bayer, Leverkusen, 100 mg/kg) and Ketonest (Parke-Davis, Berlin, 10
mg/kg). The tumors were selected in a way to minimize the differences in
their size, location, and shape. Size of all tumors was 10 mm in diameter
in order to obtain good spatial resolution of current density images.
Electrodes and electrochemotherapy
Electrochemotherapy consisted of an application of electric pulses to the
tumor 3 min after injection of bleomycin (Mack, Germany) into the
retroorbital sinus of the mouse. The dose used was 5 mg/kg (100 g per
mouse) and was well tolerated by mice. Electric pulses were delivered by
pressing on the skin four-point Pt-Ir (90–10%) alloy electrodes with a
diameter of 0.6 mm arranged in a square with a 5.5-mm distance between
each electrode. The electrodes were connected to a generator as shown in
Fig. 1. On the ventral side of the tumor, electrodes (1A and 1B) were both
connected to one pole of the generator in both the 2  1 and the 2  2
electrode sets. On the dorsal side of the tumor in the 2  1 electrode set,
only one electrode (2A) was connected to the other pole of the generator,
while in the 2  2 electrode set both dorsal electrodes (2A and 2B) were
connected to the other pole of the generator. The position of the electrode
contact with the skin with respect to the tumor is given in Fig. 2. Good
contact between the electrodes and the skin was assured by means of a
conductive gel. Eight square-wave pulses of 1300 V with a pulse width of
100 s and repetition frequency of 1 Hz were generated by electropulsator
Jouan GHT 1287 (Jouan, France). Current and voltage were monitored
FIGURE 1 Schematic presentation of electrode positioning and electri-
cal connections: (a) view in z direction (head to tail), xy plane in the model;
(b) the 2  1 electrode set in yz plane in the model; and (c) the 2  2
electrode set in yz plane in the model. The plane of observation in the tumor
is denoted by a dashed line.
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during pulse delivery. Control groups included mice without treatment,
mice treated with electric pulses, and bleomycin as a single treatment. All
treatments were performed without anesthesia and were well tolerated by
the mice.
MR current density imaging
MR current density imaging images induced current densities using MR
imager. The technique was already described in previous publications (Joy
et al., 1989; Sers˘a et al., 1994b). Theoretical consideration of sensitivity
and resolution on a model system have shown that by proper optimization
of the technique’s procedure, similar signal to noise ratios as in conven-
tional MRI can be achieved in biologically relevant experiments (Scott et
al., 1992; Sers˘a et al., 1994b). CDI was already successfully implemented
on tumors mainly to show its possible use for monitoring electrochemo-
therapy (Sers˘a et al., 1996a) and bones (Beravs et al., 1997). The technique
is based on conventional spin echo imaging sequence to which two direct
electric current pulses are added (Scott et al., 1992). First electric pulse is
applied between radio frequency 90° and 180° pulse and the second
between the radio frequency 180° pulse and the signal acquisition. The
electric pulses have the same magnitude and duration but an opposite
polarity (Fig. 3). In order to obtain a complete map of the current density,
the sample is rotated in the magnet and images are obtained in three
orthogonal directions because two directions are necessary to calculate
current density in a plane. Calculating current density ( jy) in the xz plane
requires that magnetic fields Bcurrent-x and Bcurrent-z are determined from
images in the xz plane in two sample orientations 90° apart around the y
axis.
From the complex nuclear magnetic resonance signal, phase image
modulo 2 was obtained. First, Bcurrent-x field was measured (Bo was
parallel to the x axis of the sample), and second, Bcurrent-z field was
measured (Bo was parallel to the z axis of the sample). The current density
map was calculated as a difference between a gradient in the x direction of
the Bz phase image and a gradient in the z direction of the Bx phase image
on a pixel-by-pixel basis using Ampere’s law:
jy Bcurrentz/x Bcurrentx/z/0 (1)
Current density images were obtained for the 2  1 and 2  2 electrode
sets in the observed plane (Figs. 1 and 2) and were superimposed on the
conventional MR image in the area of tumors. MRI was performed on a
100-MHz Bruker Biospec system with an imaging parameter setting of:
repetition time TR 600 ms, echo time TE 25 ms, field of view 8 cm,
slice thickness  2 mm, and matrix  256  256. Two scans were
averaged so that total imaging time was 4 min. Mice were placed into a
stereotactic frame, and four-point copper electrodes (diameter 0.6 mm) in
pairs two by two with a small amount of conductive gel were affixed to the
tumor as shown in Fig. 2. As the presence of the electrodes in the magnet
causes magnetic field inhomogeneities because of magnetic susceptibility,
pure copper (	6 ppm of iron) was used in order to minimize the distortion
of the magnetic field. The distance between the electrodes was 10 mm. The
electrodes were connected to a DC voltage amplifier as described above
and is shown in Fig. 1. The voltage applied to the tumor was 50 V with a
10-ms total duration (Tc) of current pulses. Throughout the imaging time,
electric current and voltage were monitored.
Finite element three-dimensional model
The model has been described in extenso in our previous publications
(Miklavc˘ic˘ et al., 1997; S˘emrov and Miklavc˘ic˘, 1997). Briefly, a three-
dimensional anatomically based finite element (FE) model of the mouse
with injected subcutaneous solid tumor was built using MSC/EMAS (Elec-
tro-Magnetic Analysis System) software package (trademark of The Mac-
Neal-Schwendler Corporation, Los Angeles, CA). Obtained by magnetic
resonance imaging, the geometry of the model was based on the 14
cross-section scans of one typical animal with a subcutaneous tumor. The
geometry of the model was described with 1390 points, which defined
3859 curves/line. A total of 1379 three-dimensional geometric bodies were
defined using those curves.
The resulting three-dimensional geometric structure was built of 11
different tissues (organs), i.e., skin, fat, skeletal and heart muscles, bone,
connective tissue, intestine, kidney, liver, lung, and tumor. Anisotropic
characteristics were considered for skeletal and heart muscles, whereas all
other tissues (organs) were modeled as isotropic. The values of the electric
conductivity of tissues (organs) used in the model were collected from
literature and used in one of the previous studies in which a similar model
was verified with the measurements of electric potential in the five points
in the tumor and surrounding tissue (Miklavc˘ic˘ et al., 1997). The resulting
three-dimensional model was made of 7089 three-dimensional finite ele-
ments that were defined by 7578 grid points. Fig. 2 shows the cross-section
through tumor in which the results (current density distribution) were
observed for comparison with the current density images. In addition,
electric field values inside 48 elements representing the tumor were pre-
sented for the case of 1300 V used in electrochemotherapy in form of
frequency distribution of electric field magnitudes for both electrode sets.
Mean magnitudes for electric field within the tumor for both electrode sets
were calculated and compared. Minimal and maximal values are reported
as well.
Different electrode sets were modeled by applying appropriate bound-
ary conditions in the grid points corresponding to each of the electrodes
(Figs. 1 and 2). Increased area with the same electric potential under each
electrode resulting from the use of conductive gel was also taken into
consideration. Fixed values of scalar electric potential, i.e., Dirichlet
FIGURE 2 A three-dimensional finite element model of a mouse with
subcutaneous tumor. The plane of observation in which current density
imaging was performed and current density calculated. On the model, the
position of point electrodes and their electrical connections are indicated.
FIGURE 3 Modified spin echo sequence for magnetic resonance current
density imaging.
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boundary conditions, were assigned to grid points in the regions where
electrodes were placed. Two electrode sets were modeled according to the
position of the electrodes with respect to the tumor. Potentials of 0 and 50
V for CDI and 1300 V for electrochemotherapy were assigned to groups of
appropriate grid points of the FE mesh corresponding to each of the
electrodes. In the 2  1 electrode set, the positive electrode was placed
dorsally to the tumor. In the 2  2 electrode set, the positive electrodes
were placed dorsally and cranially to the tumor. The negative electrodes
were placed on the other side ventrally to the tumor in both electrode sets.
On the remaining outer surfaces of the model, a Neumann boundary
condition was applied. This boundary was considered as the interface
between a conducting medium and air (assimilated to an ideal dielectric).
Because the conductor (skin layer) was linear and isotropic, the usual
Neumann condition was applied, i.e., the normal derivative of the electric
potential on the interface between the model and surrounding air was zero.
Total current was calculated for both electrode sets in the case of 50 V
(CDI) and 1300 V (electrochemotherapy).
Evaluation and presentation of
electrochemotherapy experiments
The effect of electrochemotherapy with the two electrode sets was tested
by performing electrotherapy on tumors when they reached 50 mm3 in
volume (day 0). Tumor volume (V) was estimated by measuring three main
mutually perpendicular tumor diameters (a, b, and c) on each consecutive
day according to Eq. 2.
Vabc/6 (2)
Mean tumor volume and standard error of the mean were then calculated
for each experimental group and presented as a tumor growth curve. For
each individual tumor, tumor doubling time was determined, i.e., the time
tumor needed to double its initial volume from day 0. For each experimental
group, mean and standard error of the mean was calculated. Tumor growth
delay GDx for experimental groups was calculated according to Eq. 3:
GDx TDx TDc (3)
in which TDx is mean tumor doubling time of a specific experimental
group x, and TDc is mean tumor doubling time of the control group.
Statistical analysis was performed on these tumor doubling times by a
Student t-test after equality of variances was tested.
RESULTS
CDI images qualitatively show the effect of the two differ-
ent electrode sets on the current density spatial distribution
FIGURE 4 Two-dimensional current density spatial distribution: (a) current density imaging (CDI) map using the 2  1 electrode set (c) and the 2 
2 electrode set, both superimposed on a conventional MR images of a mouse with solid subcutaneous tumor; (b) calculated current densities from the FE
three-dimensional model for the 2  1 and (d) the 2  2 electrode set. For CDI images, current density is given in arbitrary units, i.e., pixel intensity (a
and c). Calculated current density is given in A/m (b and d).
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through tumor. CDI maps are superimposed on the conven-
tional MR images in the tumor area (Fig. 4, a and c). When
only three-point electrodes were connected (2 1 electrode
set), a small region of higher signal intensity was observed
in the CDI image (Fig. 4 a). CDI signal was decreasing
toward the opposite side of the imaged plane where the
unconnected electrode (2B) was placed. When all four-point
electrodes were connected to the voltage amplifier (2  2
electrode set), current density throughout the imaging plane
can be observed with two regions of higher current density
(Fig. 4 c). Qualitatively similar results in spatial distribution
of current density were obtained by calculating current
density in elements of the observed plane in model (Figs. 1
and 2) at 50 V for the 2  1 electrode set (Fig. 4 b) and the
2  2 electrode set (Fig. 4 d).
Current measured during CDI was 4.7 
 0.3 mA and
6.3
 0.6 mA (mean
 standard deviation) in the 2 1 and
2  2 electrode set, respectively. Voltage was kept constant
at 50 V. For 50 V (current density imaging), total current in
the model was 4.5 mA and 6.1 mA for the 2  1 and 2 
2 electrode set, respectively.
For the case of electrochemotherapy in which 1300 V
were applied, the electric field was calculated in all 7089
elements of the mouse model. The frequency distribution of
electric field magnitudes in 48 elements representing the
tumor for both electrode sets is presented in Fig. 5. Mean
electric field obtained in the tumor was 202 V/cm with
minimal value of 115 V/cm and maximal value of 317 V/cm
in the case of the 2  1 electrode set. Mean electric field
obtained in the tumor by 2  2 electrode set was 251 V/cm
with a minimal value of 166 V/cm and a maximal value 408
V/cm. From the frequency distributions in Fig. 5, it becomes
additionally clear that in the case of the 2  2 electrode set,
a majority of elements, i.e., majority of tumor volume, is
being exposed to efficient electric field values. In the case of
the 2  1 electrode set, however, the relatively large num-
ber of elements, i.e., large portion of tumor volume, is
covered by the lowest values of electric field, presumably
below threshold field values.
Current measured during pulse delivery with the 2  1
electrode set was 1.2–2.0 A and with the 2 2 electrode set
was 2–5 A. Current was increasing from the first to the last
pulse as noted in most of pulse applications. For 1300 V
(electrochemotherapy), total current in the model was 0.12
and 0.16 A for the 2 1 and 2 2 electrode set, respectively.
The results of electrochemotherapy with both electrode
sets are given in Fig. 6 and Table 1. Tumor growth was most
retarded in experimental group of electrochemotherapy per-
formed with the 2  2 electrode set. On the contrary,
electrochemotherapy using the 2  1 electrode set was less
effective when compared with electrochemotherapy with
the 2  2 electrode set but was still more effective than
chemotherapy or electric pulses alone. Tumor growth delay
in electrochemotherapy with the 2  1 electrodes set was
7.7 
 1.3 days (mean 
 standard error) and with the 2  2
was 14.0 
 2.0 days. Tumor growth delay in electric pulses
alone and chemotherapy alone were negligible and were
0.5 
 1.3 and 0.1 
 1.5 days, respectively.
DISCUSSION
The results of our study show that spatial distribution of
current density obtained by means of CDI is qualitatively
similar to the calculated spatial distribution of current den-
sity in the observed plane using three-dimensional FE
model of a mouse with tumor. The two electrode sets we
designed, 2  2 and 2  1, indeed produced different
current density and electric field spatial distribution. In
addition, the comparison of electric field in the tumor for
both of the electrode sets with results obtained in electro-
chemotherapy experiments clearly show correlation be-
tween CDI, numerical results obtained by three-dimensional
FE model and electrochemotherapy experiments. Current
FIGURE 5 Frequency distribution of electric field magnitudes within the
tumor for both the 2  1 and the 2  2 electrode sets used in electroche-
motherapy at 1300 V.
FIGURE 6 Tumor growth after treatment on day 0. ECT, electrochemo-
therapy; BLM, bleomycin; BLM and EP 2  1 set, experimental group in
which ECT was performed with 2  1 electrode set; BLM and EP 2  2
set, experimental group in which ECT was performed with 2 2 electrode
set; EP, experimental group in which only electric pulses were delivered
(without bleomycin). Symbols, mean tumor volume; vertical bars, standard
error of the mean.
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density images obtained in both electrode sets are clearly
different in the observed plane and are qualitatively very
similar to the calculated current density distributions at
corresponding plane in the three-dimensional FE model.
The current measured during CDI for both electrode sets,
4.7 
 0.3 mA and 6.3 
 0.6 mA in the 2  1 and 2  2
electrode sets, respectively, are of the same order of value
and proportion to values calculated, respectively 4.5 and 6.1
mA. These correlation and similarity of results further val-
idate our computer model of a mouse with a tumor. The
difference in electric field magnitude and distribution
throughout the tumor resulting from numerical calculations
for both electrode sets predict also a different tumor re-
sponse to electrochemotherapy performed with 2  2 and
2  1 electrodes. This prediction was confirmed in electro-
chemotherapy by different tumor growth following electro-
chemotherapy with respective electrode sets, furthermore
validating the numerical model. Namely, the 2  2 elec-
trode set with higher electric field in the tumor when com-
pared with 2  1 electrode set, produced longer growth
delay as hypothesized in the introduction.
The results obtained in our study support previous obser-
vations that electrode geometry affects the distribution of
electric field within the tumor and therefore the effective-
ness of electrochemotherapy (Sers˘a et al., 1996b). Other
authors who compared electrochemotherapy effectiveness
when using different electrodes also demonstrated that the
geometry of electrodes used for electrochemotherapy influ-
ences its effectiveness (Gilbert et al., 1997). They, however,
did not attempt to calculate or otherwise determine electric
field distribution within the tumor, which makes their con-
clusions about the most appropriate electrodes doubtful.
The value of our approach lies in combining two different
approaches for current density distribution and electric field
determination for two electrode sets that have notable and
predictable differences. However, we have to point out that
CDI was performed at 50 V and the total current measured
and calculated for both electrode sets was similar, which
was not the case in electrochemotherapy performed at 1300
V. In the later case the currents measured during pulse
delivery were more than 10 times higher than calculated
ones. A plausible explanation is that at 50 V, tissue does not
experience electroporation, but at 1300 V conductivity of
tissue increases because of electroporation. Indeed, consid-
erably higher conductivity after electroporation was re-
ported in the literature for skin (Pliquett et al., 1995;
Prausnitz, 1996; Gallo et al., 1997) and muscle tissue (Lee
et al., 1992). This explanation is also in agreement with our
predominant observation that the current was increasing
during pulse delivery at 1300 V from the first to the last
pulse. Another limitation of our approach is that both CDI
and three-dimensional model calculations are time consum-
ing and technically demanding and are therefore not easy to
apply. Specifically, three-dimensional model if used rigor-
ously would need extensive geometric adaptations for prac-
tically each individual tumor for its size and shape. Further-
more, we need to be cautious in terms of absolute values, as
CDI does not give absolute values of current density with-
out knowing geometric properties of a measured sample,
and the three-dimensional model is very rough in terms of
exact anatomy and different tissue conductivities. In addi-
tion, threshold electric field magnitude for electroporative
permeability was not yet determined in vivo.
Despite the above stated limitations, we would like to
conclude that the complementary results obtained in our
study by means of CDI, numerical modeling, and electro-
chemotherapy experiments clearly demonstrate that the nu-
merical model we developed previously is reliable and can
be very useful in the additional search for electrodes, which
would make electrochemotherapy and in vivo electropora-
tion in general even more efficient. Our study also clearly
demonstrates that better coverage of tumors with suffi-
ciently high electric field is necessary for improved effec-
tiveness of electrochemotherapy.
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